Glenmark Pharmaceuticals Ltd
NSE :GLENMARK BSE :532296 Sector : PharmaceuticalsBuy, Sell or Hold GLENMARK? Ask The Analyst
BSE
prev close
OPEN PRICE
bid price (qty)
offer price (qty)
volume
Today's low / high
52 WK low / high
NSE
prev close
open price
bid price (qty)
offer price (qty)
volume
Today's' low / high
52 WK low / high
28 Mar 958.45 (-0.42%) | 27 Mar 962.45 (0.55%) | 26 Mar 957.20 (0.65%) | 22 Mar 951.00 (0.45%) | 21 Mar 946.70 (0.57%) | 20 Mar 941.30 (2.24%) | 19 Mar 920.65 (-2.02%) | 18 Mar 939.65 (1.42%) | 15 Mar 926.50 (-1.17%) | 14 Mar 937.50 (4.35%) | 13 Mar 898.45 (-4.94%) | 12 Mar 945.15 (-1.06%) | 11 Mar 955.30 (0.01%) | 07 Mar 955.25 (3.11%) | 06 Mar 926.40 (1.00%) | 05 Mar 917.20 (-0.49%) | 04 Mar 921.70 (-0.71%) | 02 Mar 928.25 (0.86%) | 01 Mar 920.30 (-0.52%) | 29 Feb 925.10 (1.53%) | 28 Feb 911.20 (-1.77%) |
Price Chart Historical Data Technical Chart
Technical Analysis
Short Term Investors
Very Bullish
Medium Term Investors
Very Bullish
Long Term Investors
Very Bullish
Moving Averages
5 DMA
Bullish
954.65
10 DMA
Bullish
943.6
20 DMA
Bullish
936.37
50 DMA
Bullish
901.33
100 DMA
Bullish
859.02
200 DMA
Bullish
806.94
Intraday Support and Resistance
(Based on Pivot Points) |
Updated On Mar 28, 2024 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 980.96 | 974.78 | 962.4 | - | - |
R2 | 974.78 | 969.3 | 961.08 | 974.29 | - |
R1 | 966.61 | 965.91 | 959.77 | 965.63 | 970.7 |
P | 960.43 | 960.43 | 960.43 | 959.94 | 962.48 |
S1 | 952.26 | 954.95 | 957.13 | 951.28 | 956.35 |
S2 | 946.08 | 951.56 | 955.82 | 945.59 | - |
S3 | 937.91 | 946.08 | 954.5 | - | - |
Key Metrics
EPS
37.29
P/E
25.68
P/B
1.47
Dividend Yield
0.26%
Market Cap
27,046 Cr.
Face Value
1
Book Value
651.23
ROE
6.91%
EBITDA Growth
-122.2 Cr.
Debt/Equity
0.46
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Quaterly Results
Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
INCOME | 3309.61 | 3333.5 | 3055.79 | 3327.81 | 2670.88 |
PROFIT | 148.51 | 204.3 | 182.37 | 68.79 | -393.41 |
EPS | 9.66 | -15.18 | 5.31 | -2.9 | -12.45 |
Glenmark Pharmaceuticals Ltd Quaterly Results
Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
INCOME | 2413.7 | 2172.01 | 2193.75 | 2306.99 | 1623.91 |
PROFIT | 311.75 | 436.25 | 293.58 | 317.62 | 4.87 |
EPS | 15.26 | -4.87 | 9.63 | 10.72 | -0.72 |
Profit & Loss (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | ||
INCOME | 6044.41 | 6943.01 | 7721.83 | 9576.39 | 9032.11 | 10299.46 | 10705.37 | 11227.94 | 12482.71 | 13631.99 | |
PROFIT | 542.28 | 263.52 | 743.05 | 1155.03 | 805.34 | 818.68 | 755.72 | 941.32 | 1107.67 | 561.19 | |
EPS | 20.12 | 7.3 | 26.33 | 39.29 | 28.49 | 32.78 | 27.5 | 34.38 | 35.21 | 13.37 |
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | ||
INCOME | 2466.22 | 5358.49 | 6306 | 8220.99 | 5709.21 | 6787.67 | 7289.2 | 8032.82 | 9202.67 | 9237.97 | |
PROFIT | 433.99 | 1139.79 | 1484.9 | 2322 | 1016.26 | 1344.95 | 1340.12 | 1589.58 | 1643.77 | 1578.33 | |
EPS | 15.66 | 36.72 | 52.6 | 75.86 | 35.95 | 57.49 | 48 | 58.46 | 70.8 | 42.84 |
Balance Sheet (Figures in Rs. Crores)
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 | 27.12 |
Reserves Total | 9,445.71 | 9,058.43 | 7,036.41 | 6,042.29 | 5,576.97 | 5,135.26 | 4,464.31 | 3,601.42 | 1,756.36 | 2,956.16 |
Total Shareholders Funds | 9,473.93 | 9,086.65 | 7,064.63 | 6,070.51 | 5,605.19 | 5,163.48 | 4,492.53 | 3,629.64 | 1,783.49 | 2,983.28 |
Minority Interest | 365.34 | 351.47 | -0.35 | -0.39 | -0.38 | -0.37 | -0.42 | -0.3 | -0.19 | 13.28 |
Secured Loans | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 | 353.32 |
Unsecured Loans | 4,627.24 | 3,962.02 | 4,985.72 | 4,868.63 | 4,442.56 | 4,619.64 | 4,721.06 | 3,972.58 | 3,763.24 | 2,913.66 |
Total Debt | 4,627.24 | 3,962.02 | 4,985.72 | 4,868.63 | 4,448.67 | 4,639.38 | 4,723.65 | 3,988.11 | 3,799.93 | 3,266.98 |
Other Liabilities | 397.59 | 152.5 | 196.68 | 429.27 | 89.14 | 2.6 | 32.74 | 76.99 | 121.92 | 52.13 |
Total Liabilities | 14,864.1 | 13,552.64 | 12,246.68 | 11,368.02 | 10,142.62 | 9,805.09 | 9,248.5 | 7,694.44 | 5,705.15 | 6,315.67 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 11,296.06 | 10,213.47 | 8,731.58 | 8,269.83 | 6,527.27 | 5,367.95 | 4,769.92 | 4,300.54 | 3,495.47 | 3,833.51 |
Less: Accumulated Depreciation | 5,093.68 | 4,326.23 | 3,602.73 | 3,241.28 | 2,857.01 | 2,338.4 | 2,014.83 | 1,706.99 | 1,480.09 | 742.96 |
Net Block | 6,202.38 | 5,887.24 | 5,128.85 | 5,028.55 | 3,670.26 | 3,029.55 | 2,755.09 | 2,593.55 | 2,015.38 | 3,090.55 |
Capital Work in Progress | 1,251.26 | 1,009.87 | 1,381.67 | 1,221.89 | 1,398.94 | 1,121.87 | 708.11 | 542.8 | 477.13 | 5.34 |
Investments | 44.65 | 49.62 | 24.63 | 24.59 | 29.66 | 14.66 | 15.69 | 17.2 | 17.12 | 0 |
Inventories | 2,977.79 | 2,499.83 | 2,276.83 | 2,135.62 | 2,252.07 | 2,030.59 | 2,139.05 | 1,567.76 | 1,269.04 | 932.88 |
Sundry Debtors | 4,098.61 | 3,101.14 | 2,572.06 | 2,408.96 | 2,194.59 | 2,331.81 | 2,404.32 | 2,492.65 | 2,511.77 | 2,156.34 |
Cash and Bank Balance | 1,469.7 | 1,411.52 | 1,139.16 | 1,111.24 | 937.77 | 1,234.69 | 1,057.66 | 857.12 | 775.88 | 800.67 |
Loans and Advances | 1,327.63 | 1,269.87 | 1,371.54 | 1,147.78 | 1,312.4 | 1,391.61 | 1,273.61 | 986.77 | 774.38 | 872.8 |
Total Current Assets | 9,873.72 | 8,282.35 | 7,359.58 | 6,803.61 | 6,696.83 | 6,988.69 | 6,874.64 | 5,904.3 | 5,331.07 | 4,762.69 |
Current Liabilities | 3,851.52 | 2,914.64 | 2,763.7 | 2,744.43 | 2,662.08 | 2,357.82 | 2,252.41 | 2,364.42 | 2,334.38 | 1,850.9 |
Provisions | 613.12 | 584.5 | 564.45 | 555.91 | 484.11 | 432.46 | 262.95 | 134.03 | 216.78 | 259.95 |
Total Current Liabilities & Provisions | 4,464.64 | 3,499.14 | 3,328.16 | 3,300.34 | 3,146.18 | 2,790.28 | 2,515.36 | 2,498.44 | 2,551.16 | 2,110.86 |
Net Current Assets | 5,409.08 | 4,783.21 | 4,031.42 | 3,503.27 | 3,550.65 | 4,198.41 | 4,359.27 | 3,405.86 | 2,779.91 | 2,651.83 |
Deferred Tax Assets | 2,090.6 | 1,969.55 | 1,852.18 | 1,770.85 | 1,761.63 | 1,728.58 | 1,553.35 | 1,274.96 | 169.73 | 721.3 |
Deferred Tax Liability | 327.64 | 314.93 | 346.26 | 331.59 | 378.68 | 408.32 | 242.08 | 210.07 | 222.52 | 207.08 |
Net Deferred Tax | 1,762.96 | 1,654.62 | 1,505.92 | 1,439.26 | 1,382.95 | 1,320.26 | 1,311.27 | 1,064.89 | -52.79 | 514.22 |
Other Assets | 193.75 | 168.08 | 174.18 | 150.45 | 110.16 | 120.34 | 99.06 | 70.15 | 468.42 | 53.72 |
Total Assets | 14,864.08 | 13,552.65 | 12,246.67 | 11,368.01 | 10,142.61 | 9,805.09 | 9,248.49 | 7,694.44 | 5,705.16 | 6,315.66 |
Contingent Liabilities | 336.69 | 361.31 | 384.2 | 271.21 | 73.51 | 47.1 | 36.88 | 36.89 | 129.37 | 129.44 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 | 27.12 |
Reserves Total | 17,849.25 | 16,710.37 | 14,781.29 | 13,198.05 | 11,913.87 | 10,363.22 | 9,408.4 | 7,337.75 | 4,924.92 | 2,878.9 |
Total Shareholders Funds | 17,877.47 | 16,738.59 | 14,809.51 | 13,226.27 | 11,942.09 | 10,391.44 | 9,436.62 | 7,365.97 | 4,952.05 | 2,906.02 |
Secured Loans | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 | 1.47 |
Unsecured Loans | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,128.37 | 2,961.33 | 2,773.94 | 771.89 | 373.41 | 351.85 |
Total Debt | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,134.48 | 2,981.07 | 2,776.53 | 787.42 | 410.1 | 353.32 |
Other Liabilities | 372.58 | 121.32 | 136.61 | 205.65 | 88.51 | 2.6 | 2.41 | 4.7 | 121.92 | 51.88 |
Total Liabilities | 21,471.27 | 20,597.61 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.09 | 5,484.07 | 3,311.22 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 3,183.65 | 3,026.28 | 2,848.56 | 2,595.06 | 2,260.1 | 2,581.75 | 2,368.53 | 2,107.04 | 1,801.98 | 658.02 |
Less : Accumulated Depreciation | 1,437.7 | 1,273.95 | 1,126.07 | 983.11 | 846.62 | 882.63 | 772.16 | 669.04 | 571.3 | 209.5 |
Net Block | 1,745.95 | 1,752.33 | 1,722.49 | 1,611.95 | 1,413.48 | 1,699.12 | 1,596.37 | 1,438 | 1,230.68 | 448.52 |
Capital Work in Progress | 172.34 | 109.04 | 131.4 | 200.01 | 286.2 | 419.68 | 270.66 | 276.06 | 294.19 | 83.31 |
Investments | 10,334.01 | 8,559.39 | 6,989.95 | 4,713.93 | 3,268.75 | 3,212.68 | 1,866.7 | 1,858.43 | 1,659.52 | 1,409.24 |
Inventories | 1,090.21 | 951.66 | 762.39 | 837.5 | 911.21 | 1,111.18 | 1,145.06 | 968 | 736.63 | 210.43 |
Sundry Debtors | 2,505.66 | 2,678.32 | 2,488.75 | 1,835.24 | 2,087.13 | 3,828.91 | 3,879.4 | 3,057.66 | 2,440.83 | 1,136.04 |
Cash and Bank Balance | 93.79 | 29.63 | 15.79 | 88.26 | 256.48 | 177.38 | 252.18 | 74.24 | 48.55 | 108.46 |
Loans and Advances | 695.51 | 743.31 | 1,642.2 | 1,662.89 | 1,886.33 | 757.78 | 674.19 | 528.03 | 371.94 | 154.69 |
Total Current Assets | 4,385.18 | 4,402.93 | 4,909.12 | 4,423.89 | 5,141.15 | 5,875.25 | 5,950.83 | 4,627.93 | 3,597.95 | 1,609.61 |
Current Liabilities | 2,952.14 | 2,168.39 | 1,834.31 | 1,827.48 | 1,855.86 | 1,796.56 | 1,727.02 | 1,867.56 | 1,882.99 | 786.32 |
Provisions | 162.52 | 148.49 | 133.11 | 118.45 | 121.75 | 93.2 | 57.97 | 87.37 | 151.38 | 95.64 |
Total Current Liabilities & Provisions | 3,114.66 | 2,316.88 | 1,967.41 | 1,945.92 | 1,977.62 | 1,889.76 | 1,784.98 | 1,954.93 | 2,034.37 | 881.96 |
Net Current Assets | 1,270.52 | 2,086.05 | 2,941.71 | 2,477.97 | 3,163.54 | 3,985.49 | 4,165.85 | 2,672.99 | 1,563.58 | 727.65 |
Deferred Tax Assets | 1,160.25 | 1,137.47 | 1,118.72 | 1,081.34 | 1,063.23 | 1,056.45 | 820.62 | 589.41 | 24.84 | 10.26 |
Deferred Tax Liability | 213.5 | 214.2 | 265.43 | 276.6 | 351.1 | 395.83 | 226.56 | 188.25 | 157.23 | 46.67 |
Net Deferred Tax | 946.75 | 923.27 | 853.29 | 804.74 | 712.13 | 660.62 | 594.06 | 401.16 | -132.39 | -36.41 |
Other Assets | 7,001.7 | 7,167.54 | 6,011.27 | 7,197.08 | 6,320.98 | 3,397.52 | 3,721.92 | 1,511.43 | 868.49 | 678.91 |
Total Assets | 21,471.26 | 20,597.62 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.08 | 5,484.07 | 3,311.21 |
Contingent Liabilities | 3,443.3 | 3,325.06 | 3,730.17 | 4,430.59 | 3,680.94 | 4,549.6 | 3,720.76 | 4,594.01 | 5,326.65 | 3,284.76 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 868.45 |
Depreciation | 611.27 |
Interest (Net) | 326.82 |
Dividend Received | 0.35 |
P/L on Sales of Assets | -5.73 |
Prov. and W/O (Net) | 53.52 |
P/L in Forex | -286.16 |
Total Adjustments (PBT and Ext... | 1,471.96 |
Operating Profit before Workin... | 2,340.41 |
Trade and 0ther Receivables | -848.74 |
Inventories | -375.17 |
Trade Payables | 166.21 |
Total Adjustments (OP before W... | -1,074.48 |
Cash Generated from/(used in) ... | 1,265.93 |
Direct Taxes Paid | -640.54 |
Total Adjustments(Cash Generat... | -640.54 |
Cash Flow before Extraordinary... | 625.39 |
Net Cash from Operating Activi... | 625.39 |
Purchased of Fixed Assets | -607.76 |
Sale of Fixed Assets | 57.23 |
Purchase of Investments | -6.01 |
Sale of Investments | 5 |
Interest Received | 22.77 |
Net Cash used in Investing Act... | -515.44 |
Proceed from 0ther Long Term B... | 1,163.19 |
On Redemption of Debenture | -152.73 |
Of the Long Tem Borrowings | -513.22 |
Of the Short Term Borrowings | -20 |
Of Financial Liabilities | -106.55 |
Dividend Paid | -136.61 |
Interest Paid | -311.54 |
Net Cash used in Financing Act... | -77.46 |
Net Profit before Tax and Extr... | 1,571.87 |
Depreciation | 184.15 |
Interest (Net) | 22.68 |
Dividend Received | 320.09 |
P/L on Sales of Assets | -5.63 |
Prov. and W/O (Net) | 25.02 |
P/L in Forex | -279.51 |
Others | -152.73 |
Total Adjustments (PBT and Ext... | 122.48 |
Operating Profit before Workin... | 1,694.35 |
Trade and 0ther Receivables | 141.32 |
Inventories | -138.55 |
Trade Payables | 149.79 |
Total Adjustments (OP before W... | 196.13 |
Cash Generated from/(used in) ... | 1,890.48 |
Direct Taxes Paid | -416.42 |
Total Adjustments(Cash Generat... | -416.42 |
Cash Flow before Extraordinary... | 1,474.06 |
Net Cash from Operating Activi... | 1,474.06 |
Purchased of Fixed Assets | -189.62 |
Sale of Fixed Assets | 316.54 |
Sale of Investments | 5 |
Interest Received | 313.19 |
Invest.In Subsidiaires | -3.12 |
Loans to Subsidiaires | -1,193.44 |
Net Cash used in Investing Act... | -431.52 |
Of the Long Tem Borrowings | -513.22 |
Of the Short Term Borrowings | -20 |
Of Financial Liabilities | -32.31 |
Dividend Paid | -70.43 |
Interest Paid | -189.81 |
Net Cash used in Financing Act... | -978.5 |
Company Details
Registered Office |
|
Address | B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Registrars |
|
Address | B/2 Mahalaxmi Chambers |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Management |
|
Name | Designation |
Glenn Saldanha | Chairman / Executive Director |
Cheryl Pinto | Executive Director (Corporate) |
V S Mani | Executive Director & Group CFO |
B E Saldanha | Non Executive Director |
Rajesh Desai. | Independent Non Exe. Director |
Devendra Raj Mehta | Independent Non Exe. Director |
Bernard Munos | Independent Non Exe. Director |
Brian W Tempest | Independent Non Exe. Director |
Sridhar Gorthi | Independent Non Exe. Director |
Sona Saira Ramasastry | Independent Non Exe. Director |
Dipankar Bhattacharjee | Independent Non Exe. Director |
V R Iyer | Independent Non Exe. Director |